Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Browse By Topic
Economics & Value
Economics & Value
Articles about real-world healthcare utilization and costs on Value-Based Cancer Care.
Filter by Topic
Accountable Care Organization
Community Oncology
Comparative Effectiveness
Comparative Effectiveness Research
Economics of Cancer Care
Health Economics
Oncology Benefit Edition
Payer-Provider
Pricing
Reimbursement
Value-Based Care
Urologists’ Prescribing of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer Vary by Practice Affiliation
Economics & Value
,
Economics of Cancer Care
June 2013, Vol 4, No 5
An analysis comparing the prescribing habits of urology practices shows that, despite treatment guideline recommendations to the contrary, gonadotropin-releasing hormone (GnRH) agonists, which are only indicated for the palliative treatment of advanced prostate cancer, are routinely prescribed for patients with localized, low- or intermediate-grade prostate cancer, particularly by urologists who have no practice affiliation with a medical school.
Read Article
Single, Older Women Less Likely to Receive Guideline- Recommended Treatment for Breast Cancer in Rural Georgia
Economics & Value
,
Economics of Cancer Care
June 2013, Vol 4, No 5
;Researchers looking at whether guideline-directed adjuvant treatments for breast cancer were actually being administered in rural areas of the United States found that only 41% of the patients in this study received all of the suggested treatment modalities for breast cancer.
Read Article
Use of High-Cost Tests for Lung Cancer Surveillance Rising
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
June 2013, Vol 4, No 5
The use of costly diagnostic imaging of uncertain value is increasing rapidly for patients with localized non–small-cell lung cancer (NSCLC), according to data from the Surveillance, Epidemiology and End Results (SEER)-Medicare database.
Read Article
Cancer Support Program Documents Savings
By
Caroline Helwick
Economics & Value
,
Economics of Cancer Care
May 2013, Vol 4, No 4
A case management program for terminally ill patients with cancer can reduce cancer-related healthcare costs and extend hospice length of stay, according to an analysis of the Cancer Support Program (CSP) of Optum Health, a health services company, which was presented at the 2013 National Comprehensive Cancer Network
®
annual conference.
Read Article
Neoadjuvant Chemotherapy Reduces Costs for Older Patients with Ovarian Cancer
By
Charles Bankhead
Economics & Value
,
Economics of Cancer Care
May 2013, Vol 4, No 4
Neoadjuvant chemotherapy for older patients with ovarian cancer would save $19 million annually compared with primary debulking surgery, based on a new cost- model assessment
Read Article
Palliative Care Cost-Effective for Platinum-Resistant Ovarian Cancer
By
Charles Bankhead
Economics & Value
,
Economics of Cancer Care
,
Palliative Care
May 2013, Vol 4, No 4
Early palliative care proved to be cost-effective and cost-saving versus routine end-of-life care for patients with recurrent platinum-resistant ovarian cancer, according to a decision-model analysis.
Read Article
Aetna’s Value-Based Process Improvement for the Survival of Community Oncology
By
Caroline Helwick
Economics & Value
,
Value-Based Care
May 2013, Vol 4, No 4
Hollywood, FL—Community oncology will not survive in the absence of novel management strategies and process improvements, according to Michael Kolodziej, MD, FACP, National Medical Director of Oncology Solutions, who offered his insights at the Third Annual Conference of the Association for Value-Based Cancer Care.
Read Article
WellPoint’s Perspective on Value-Based Cancer Care for Today and Tomorrow
By
Caroline Helwick
Economics & Value
,
Value-Based Care
May 2013, Vol 4, No 4
Read Article
Most Women Not Willing to Pay for Genetic Breast Cancer Testing
By
Caroline Helwick
Economics & Value
,
Health Economics
February 2013, Vol 4, No 2
Direct-to-consumer (DTC) genetic testing using single nucleotide polymorphisms (SNPs) is of interest to women who are concerned about breast cancer; however, these women are unwilling to pay the current costs, researchers from the Department of Surgery and Institute for Health Policy Studies, University of California, San Francisco (UCSF), Medical Center, reported at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.
Read Article
Costs of Second-Line Metastatic Colorectal Cancer Treatments Compared
By
Caroline Helwick
Economics & Value
,
Health Economics
February 2013, Vol 4, No 2
San Francisco, CA—For the second- line treatment of patients with metastatic colorectal cancer (CRC), the total costs were 14% lower with bevacizumab (Avastin) than with cetuximab (Erbitux), according to an analysis presented at the 2013 Gastrointestinal Cancers Symposium.
Read Article
Page 15 of 18
12
13
14
15
16
17
18
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
Talvey Receives Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma